Clinical Trial

Screening for High Frequency Malignant Disease

Study acronym: SHIELD
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2026-07-30 -> 2026-12-31 2026-05-01
minor Completion pushed: 2026-07-30 -> 2026-12-31 2026-05-01
notable Primary completion pushed: 2026-04-30 -> 2026-07-30 2026-04-04
minor Completion pushed: 2026-04-30 -> 2026-07-30 2026-04-04
Trial Details
NCT Number NCT05117840
Lead Sponsor Guardant Health, Inc.
Conditions Lung Cancer
Enrollment 12,000 participants
Start Date 2022-01-13
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-06